Bora Pharmaceuticals Co., Ltd. has made a strategic investment in Tanvex Biopharma Co., Ltd., under which Bora Biologics, a subsidiary of Bora and specialist large molecule CDMO, and Tanvex will combine their biomanufacturing facilities to create a global service for biologics development and supply. The investment combines Bora’s CDMO capabilities with Tanvex’s scale, development expertise and U.S. FDA-approved commercial-scale facility in San Diego, CA. Additionally, Bobby Sheng, Chairman and CEO of the Bora Group, has been appointed Chairman of the merged organization. 
 
Upon completion of the transaction, which is expected in 1Q25, Bora will hold approximately 30.5% of Tanvex’s total outstanding shares based on current shareholding structure, becoming the single largest shareholder of Tanvex.
 
Bora Pharmaceuticals is a global CDMO with 10 state-of-the-art factories around the world. Upon completion, the company will closely collaborate with Tanvex to leverage its global CDMO operations and capabilities to provide comprehensive services to biologics customers, including Bora’s new fill/finish capabilities in Maryland, U.S. Tanvex has created a strong biologics development and manufacturing operations in both the U.S. and Taiwan.
 
Combined, these capabilities offer a global development and manufacturing platform to biologics customers both in U.S. and Asia. Tanvex brings over 100,000 sq.-ft. of biomanufacturing space and 1,000-liter bioreactors, which complement Bora’s 500-liter bioreactors to provide a scalable service offering. 
​
“This strategic investment focuses on both parties’ shared vision for the biologics CDMO business,” said Bobby Sheng. “It combines Bora’s strong reputation, industry leading quality and global operational resources with Tanvex’s established USFDA-approved commercial scale biologics facility and biosimilar expertise in San Diego. This partnership will enable the combined entity to rapidly respond to evolving industry demands and policy developments, such as the BIOSECURE Act in the US, and capitalize on new opportunities in onshoring, friendshoring, and the growing CDMO demands driven by these policy changes.”   
​
Henry Chen, Chairman and CEO of Tanvex, added, “Tanvex has been dedicated to the development and manufacturing of biologics since its inception and now offers an integrated suite of services from early stage non-GMP pre-clinical development to commercial stage CGMP manufacturing. The strategic investment by Bora presents an optimal opportunity combine our strengths with Bora’s proven success in building a global CDMO platform characterized by exceptional quality, excellent manufacturing track-record and strong customer relationships.”
​
Related News
Bora Pharmaceuticals Completes Upsher-Smith Acquisition

Bora Pharmaceuticals Completes Acquisition of Emergent’s US Sterile Fill/Finish Facility